Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma

被引：3

作者：

Tang, Quanqing ^{[1
]}

Li, Shihao ^{[1
]}

Huang, Gaozhen ^{[1
]}

Liu, Hongwei ^{[1
]}

机构：

[1] Guangdong Med Univ, Dept Urol, Affiliated Hosp, Zhanjiang, Guangdong, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2023年 / 119卷

关键词：

Metastatic urothelial carcinoma; Immune checkpoint inhibitor; Programmed death-1; Programmed death-ligand 1; Immunotherapy; CISPLATIN-INELIGIBLE PATIENTS; IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; SINGLE-ARM; CLINICAL ACTIVITY; GENE-EXPRESSION; ADVERSE EVENTS; CANCER; MULTICENTER; PEMBROLIZUMAB;

D O I：

10.1016/j.intimp.2023.110158

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Urothelial carcinoma (UC) is a very common malignant tumor. In the past few decades, platinum-based chemotherapy has been regarded as the standard recommended regimen for patients with metastatic urothe-lial carcinoma (mUC) who can receive either cisplatin or carboplatin. The emergence of immune checkpoint inhibitors (ICIs) brought some hope for possible treatments for mUC patients who were unfit for platinum therapy. ICIs drugs have emerged as new potential weapons to overcome UC in our lifetime. ICIs block the binding of programmed death-1 (PD-1) to programmed death-ligand 1 (PD-L1), leading to enhancement of the immune function of antitumor T cells. In the treatment of UC, ICIs show an apparent ascendancy and effectively enhance survival rates. With good tolerability and remarkable effects, ICIs have given thousands of patients hope. This article mainly shows the application of PD-1 and PD-L1 inhibitors in mUC.

引用

页数：8

共 65 条

[21] Avelumab: First Global Approval [J].

Kim, Esther S. .

DRUGS, 2017, 77 (08) :929-937

[22] Tislelizumab: First Approval [J].

Lee, Arnold ;

Keam, Susan J. .

DRUGS, 2020, 80 (06) :617-624

[23] TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells [J].

Mariathasan, Sanjeev ;

Turley, Shannon J. ;

Nickles, Dorothee ;

Castiglioni, Alessandra ;

Yuen, Kobe ;

Wang, Yulei ;

Kadel, Edward E., III ;

Koeppen, Hartmut ;

Astarita, Jillian L. ;

Cubas, Rafael ;

Jhunjhunwala, Suchit ;

Banchereau, Romain ;

Yang, Yagai ;

Guan, Yinghui ;

Chalouni, Cecile ;

Ziai, James ;

Senbabaoglu, Yasin ;

Santoro, Stephen ;

Sheinson, Daniel ;

Hung, Jeffrey ;

Giltnane, Jennifer M. ;

Pierce, Andrew A. ;

Mesh, Kathryn ;

Lianoglou, Steve ;

Riegler, Johannes ;

Carano, Richard A. D. ;

Eriksson, Pontus ;

Hoglund, Mattias ;

Somarriba, Loan ;

Halligan, Daniel L. ;

van der Heijden, Michiel S. ;

Loriot, Yohann ;

Rosenberg, Jonathan E. ;

Fong, Lawrence ;

Mellman, Ira ;

Chen, Daniel S. ;

Green, Marjorie ;

Derleth, Christina ;

Fine, Gregg D. ;

Hegde, Priti S. ;

Bourgon, Richard ;

Powles, Thomas .

NATURE, 2018, 554 (7693) :544-+

[24] Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer [J].

Massard, Christophe ;

Gordon, Michael S. ;

Sharma, Sunil ;

Rafii, Saeed ;

Wainberg, Zev A. ;

Luke, Jason ;

Curiel, Tyler J. ;

Colon-Otero, Gerardo ;

Hamid, Omid ;

Sanborn, Rachel E. ;

O'Donnell, Peter H. ;

Drakaki, Alexandra ;

Tan, Winston ;

Kurland, John F. ;

Rebelatto, Marlon C. ;

Jin, Xiaoping ;

Blake-Haskins, John A. ;

Gupta, Ashok ;

Segal, Neil H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) :3119-+

[25] Immune checkpoint inhibitors for metastatic bladder cancer [J].

Massari, Francesco ;

Di Nunno, Vincenzo ;

Cubelli, Marta ;

Santoni, Matteo ;

Fiorentino, Michelangelo ;

Montironi, Rodolfo ;

Cheng, Liang ;

Lopez-Beltran, Anto ;

Battelli, Nicola ;

Ardizzoni, Andrea .

CANCER TREATMENT REVIEWS, 2018, 64 :11-20

[26] Cancer immunotherapy comes of age [J].

Mellman, Ira ;

Coukos, George ;

Dranoff, Glenn .

NATURE, 2011, 480 (7378) :480-489

[27] Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma [J].

Miron, Benjamin ;

Geynisman, Daniel M. .

EUROPEAN UROLOGY, 2022, 82 (04) :374-376

[28] Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial [J].

Patel, Manish R. ;

Ellerton, John ;

Infante, Jeffrey R. ;

Agrawal, Manish ;

Gordon, Michael ;

Aljumaily, Raid ;

Britten, Carolyn D. ;

Dirix, Luc ;

Lee, Keun-Wook ;

Taylor, Mathew ;

Schoffski, Patrick ;

Wang, Ding ;

Ravaud, Alain ;

Gelb, Arnold B. ;

Xiong, Junyuan ;

Rosen, Galit ;

Gulley, James L. ;

Apolo, Andrea B. .

LANCET ONCOLOGY, 2018, 19 (01) :51-64

[29] Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study [J].

Plimack, Elizabeth R. ;

Bellmunt, Joaquim ;

Gupta, Shilpa ;

Berger, Raanan ;

Chow, Laura Q. M. ;

Juco, Jonathan ;

Lunceford, Jared ;

Saraf, Sanatan ;

Perini, Rodolfo F. ;

O'Donnell, Peter H. .

LANCET ONCOLOGY, 2017, 18 (02) :212-220

[30] Camouflage and sabotage: tumor escape from the immune system [J].

Poschke, Isabel ;

Mougiakakos, Dimitrios ;

Kiessling, Rolf .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (08) :1161-1171

← 1 2 3 4 5 6 7 →